Literature DB >> 31956135

Recovered Left Ventricular Ejection Fraction and Its Prognostic Impacts in Hospitalized Heart Failure Patients with Reduced Ejection Fraction.

Satoshi Abe1, Akiomi Yoshihisa1,2, Yasuhiro Ichijo1, Yu Sato1, Yuki Kanno1, Mai Takiguchi1, Tetsuro Yokokawa1,3, Tomofumi Misaka1,2, Takamasa Sato1, Masayoshi Oikawa1, Atsushi Kobayashi1, Takayoshi Yamaki1, Hiroyuki Kunii1, Yasuchika Takeishi1.   

Abstract

It has been recently recognized that recovery of left ventricular ejection fraction (EF), termed "recovered EF", occurs in a proportion of heart failure patients with reduced EF (HFrEF), and is associated with better prognosis. However, the clinical characteristics of "recovered EF" have not been fully examined.Consecutive 567 patients hospitalized due to HFrEF (EF < 40% at 1st assessment at hospital discharge) were enrolled, and EF was re-assessed within half a year in an outpatient setting (2nd assessment). Among these HFrEF patients, 235 remained EF < 40% (reduced, rEF group), 82 changed to EF 40-49% (midrange, mrEF group), and 250 recovered to EF > 50% (preserved, pEF group "recovered EF" ) at the 2nd examination. Age was lower and body mass index and systolic blood pressure were higher in pEF than in rEF. The prevalence of atrial fibrillation (AF) and usage of an implantable cardiac defibrillator and cardiac resynchronization therapy were highest in pEF. Left ventricular end diastolic dimension (LVDd) was the smallest in the pEF group. Multivariable logistic regression analysis revealed that younger age, presence of AF, and lower levels of LVDd were predictors of "recovered EF". Kaplan-Meier analysis found that pEF presented the lowest cardiac event rate (P = 0.003) and all-cause mortality (P = 0.001). In multivariable Cox proportional hazard analyses, pEF (versus rEF) was an independent predictor of both cardiac event rate (HR = 0.668, 95%CI 0.450-0.994, P = 0.046) and all-cause mortality (HR = 0.655, 95%CI 0.459-0.934, P = 0.019).Hospitalized HFrEF patients with recovered EF are associated with younger age, higher presence of AF, and better prognosis.

Entities:  

Keywords:  Co-morbidity; Prognosis; Recover

Year:  2020        PMID: 31956135     DOI: 10.1536/ihj.19-211

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  5 in total

1.  Reverse Remodeling in Human Heart Failure after Cardiac Resynchronization Therapy Is Associated With Reduced RHO-Kinase Activation.

Authors:  Maria Paz Ocaranza; Jorge E Jalil; Rodrigo Altamirano; Ana de León; Jackeline Moya; Alejandra Lonis; Luigi Gabrielli; Paul Mac Nab; Samuel Córdova; Alejandro Paredes; Ismael Vergara; Alex Bittner; Karime Sabat; Karla Pastorini
Journal:  Front Pharmacol       Date:  2021-04-23       Impact factor: 5.810

Review 2.  Female Gender Is Associated with an Increased Left Ventricular Ejection Fraction Recovery in Patients with Heart Failure with Reduced Ejection Fraction.

Authors:  Jakrin Kewcharoen; Angkawipa Trongtorsak; Sittinun Thangjui; Chanavuth Kanitsoraphan; Narut Prasitlumkum
Journal:  Med Sci (Basel)       Date:  2022-04-02

3.  Body Mass Index: An Effective Predictor of Ejection Fraction Improvement in Heart Failure.

Authors:  Li-Fang Ye; Xue-Ling Li; Shao-Mei Wang; Yun-Fan Wang; Ya-Ru Zheng; Li-Hong Wang
Journal:  Front Cardiovasc Med       Date:  2021-12-01

4.  Predictors and Mortality for Worsening Left Ventricular Ejection Fraction in Patients With HFpEF.

Authors:  Liling Chen; Zhidong Huang; Xiaoli Zhao; Jingjing Liang; Xiaozhao Lu; Yibo He; Yu Kang; Yun Xie; Jin Liu; Yong Liu; Jin Yang; Weixu Yu; Wanling Deng; Yuxiong Pan; Jin Lu; Yanfang Yang; Xujing Xie; Xiaoxian Qian; Qingbo Xu; Longtian Chen; Kaihong Chen; Shiqun Chen
Journal:  Front Cardiovasc Med       Date:  2022-02-24

5.  The beneficial impact of cardiac rehabilitation on obstructive sleep apnea in patients with coronary artery disease.

Authors:  Danuta Loboda; Michalina Stepanik; Agata Golba; Monika Dzierzawa; Anna Szajerska-Kurasiewicz; Karolina Simionescu; Maciej Turski; Sylwia Kucia-Kuzma; Jacek Durmala; Krzysztof S Golba
Journal:  J Clin Sleep Med       Date:  2021-03-01       Impact factor: 4.062

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.